CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 43 enrolled
Drug / intervention
Enoxaparindrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00420667
NCT00420667N/ACompleted

Effect of Low Molecular Weight Heparin vs Unfractionated Heparin on Bleeding After Cardiac Surgery

G. d'Annunzio University·interventional·Posted Jan 11, 2007·Updated Nov 14, 2022

In Brief

A clinical study evaluating Enoxaparin for Coronary Disease and Coronary Artery Bypass Grafting. Completed, enrolled 43 participants across 1 site.

Detailed Summary

Because the impairment of platelet function may cause excess peri-operative bleeding, pre-operative aspirin discontinuation and heparin bridging are common at cardiac surgery. We aimed to evaluate the impact of a low-molecular-weight-heparin (LMWH), enoxaparin, and unfractionated heparin (UFH) on coagulation parameters and peri-operative bleeding in patients undergoing elective coronary artery bypass grafting (CABG) surgery after aspirin discontinuation. The specific hypothesis of this study was that a 12 h interval is sufficient not to cause excess peri-operative bleeding, and is therefore an optimal compromise between antithrombotic efficacy and haemorrhagic safety.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
CountriesItaly
Collaborators--

Timeline

N/ACompletedFinished
20052006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedJan 11, 2007
Enrollment StartNov 1, 2004
Primary CompletionMar 1, 2005
Study CompletionMay 1, 2005
TodayJul 2, 2026
Enrollment to primary: 4 monthsPosted 19.5 years ago

Interventions

Enoxaparindrug